Sort
48,018 grants matching “immunotherapy”
DEVELOPING NOVEL IMMUNOTHERAPY TO SUPPRESS CANCER METASTASIS AND RECURRENCE IN BONE
$1,419,356Brigham & Womens Hospital Inc · · FY2021 · Defense Health Agency
Gene Discovery
$1,418,774Ira Pastan · Basic Sciences · Z01 · FY2007 · CA
Late-stage development and de-risking of a novel monoclonal antibody immunotherapy for EGFR-positive solid cancers
$1,418,424Howard M Stern · Tigatx Inc · R44 · FY2024 · CA
Radiation-induced molecular targets
$1,416,630Norman Coleman · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders
$1,416,172Julie R Park · Seattle Children'S Hospital · U01 · FY2019 · TR
Sinonasal and Olfaction Program
$1,415,699Joshua Levy · National Institute On Deafness And Other Communication Disorders · ZIA · FY2024 · DC
THERAPY OF HIV WITH GENETICALLY MODIFIED T CELL CLONES
$1,415,461Fred Hutchinson Cancer Research Center · P01 · FY2000 · AI
LIAI Epitope Validation Center: Characterization of Allergen specific T Cells
$1,415,451Alessandro Sette · La Jolla Institute For Immunology · U19 · FY2014 · AI
Novel Strategies for Brain Tumor Therapy
$1,415,436University Of Pittsburgh At Pittsburgh · P01 · FY2005 · NS
SVEU - Operation of a NHP Breeding Colony
$1,414,508Peter Silvera · Advanced Bioscience Laboratories, Inc. · N01 · FY2020 · AI
Cellular Interactions with Thrombospondin
$1,414,291David D Roberts · Division Of Clinical Sciences - Nci · ZIA · FY2018 · CA
Simian Vaccine Evaluation Unit (SVEU)
$1,413,590Michael Agy · University Of Washington · N01 · FY2013 · AI
Synthetic Cell State Engineering for Primary Human Cellular Therapies
$1,413,277Theodore Lee Roth · Stanford University · DP2 · FY2025 · CA
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis
$1,413,190Jerrold J. Ellner · Boston Medical Center · U19 · FY2018 · AI
Administrative Core for SWOG SDMC
$1,413,005Michael Leo Leblanc · Fred Hutchinson Cancer Center · U10 · FY2023 · CA
Next generation T cell therapies for mutant KRAS solid tumors
$1,412,213Beatriz M. Carreno · University Of Pennsylvania · UG3 · FY2024 · CA
ADULT AIDS CLINICAL TRIALS UNIT
$1,411,698David B Clifford · Washington University · U01 · FY2006 · AI
Strategies to Overcome Immune Resistance in Head and Neck Cancers
$1,411,624Sara Isabel Pai · Yale University · P01 · FY2023 · CA
Cellular Interactions with Thrombospondin
$1,411,277David D Roberts · Division Of Clinical Sciences - Nci · ZIA · FY2023 · CA
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1
$1,411,211Nilu Goonetilleke · Univ Of North Carolina Chapel Hill · U01 · FY2021 · AI
UCLA SPORE IN LUNG CANCER
$1,410,484University Of California Los Angeles · P50 · FY2001 · CA
Antibody dependent cellular cytotoxicity and HIV-1 mother to child transmission
$1,407,828Manish Sagar · Boston Medical Center · R01 · FY2025 · AI
Cellular & Inflammatory Pathways in Ashtma & Allergic Diseases: From IgE to Cells
$1,407,706Lawrence Barry Schwartz · Virginia Commonwealth University · U19 · FY2009 · AI
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
$1,407,704David E Fisher · Massachusetts General Hospital · P01 · FY2016 · CA
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
$1,407,704David E Fisher · Massachusetts General Hospital · P01 · FY2017 · CA